Skip to content
Search

Latest Stories

Covid pushes UK car output to lowest level since 1984

Covid pushes UK car output to lowest level since 1984

BRITISH car output fell to its lowest level since 1984 last year after the Covid-19 pandemic shut factories and hurt demand, an industry body said on Thursday(28), as a decision on keeping open the Vauxhall car factory looms.

A total of 920,928 cars rolled off production lines in 2020, down 29 per cent on 2019, according to the Society of Motor Manufacturers and Traders, as some plants shut for several months and many still run at below-normal levels.


"These figures, the worst in a generation, reflect the devastating impact of the pandemic on UK automotive production, with Covid lockdowns depressing demand, shuttering plants and threatening lives and livelihoods," said SMMT chief executive Mike Hawes.

Investment, however, was a bright spot, rising to £3.2 billion ($4.4bn), the highest figure since 2014, due largely to plans by startup Britishvolt to build a battery gigafactory in northern England.

Jaguar Land Rover saw its British output fall 37 per cent to 243,908 cars as Nissan overtook it to become the country's biggest automotive maker, producing 245,649 vehicles at its Sunderland site in North East England , according to SMMT figures.

Output is only expected to recover slightly to 1 million vehicles in 2021, as the effect of the coronavirus continues and Honda's Swindon factory, which made nearly 70,000 vehicles in 2020, permanently closes.

Earlier this month, Carlos Tavares, the chief executive of Vauxhall's parent company, warned about the future of its Ellesmere Port factory in northern England, where it makes the Vauxhall/Opel Astra.

He called on prime minister Boris Johnson's administration to show willingness to protect the sector. A decision on whether the site will build new vehicles or close is due in the next few weeks.

"As far as the government is concerned, it will want to try and sustain and do everything it can to help secure that future investment, having backed the sector in the (Brexit) negotiations with Europe," said Hawes.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less